Augmentation strategies for treatment-resistant depression

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Many patients with depression do not achieve remission with standard antidepressant treatments.
• These individuals are diagnosed with treatment-resistant depression (TRD), characterized by high relapse rates.
• Augmentation pharmacotherapy involves adding non-antidepressant drugs to enhance the efficacy of existing antidepressant regimens.

Purpose of the Study:

• To review the current status of augmentation treatments for TRD.
• To explore future research directions in TRD augmentation therapies.
• To focus on research data published within the past year.

Main Methods:

• Review of clinical trials investigating augmentation strategies for TRD.
• Analysis of studies on atypical antipsychotics, stimulants, pindolol, lithium, lamotrigine, and mecamylamine.
• Evaluation of recent data on augmentation efficacy, particularly for selective serotonin reuptake inhibitor-resistant depression.

Main Results:

• Several agents including atypical antipsychotics, lithium, and lamotrigine have been tested for TRD augmentation.
• Many trials had limitations such as lack of control groups or small sample sizes.
• Emerging evidence supports the use of certain atypical antipsychotics to augment treatment for depression resistant to newer antidepressants.

Conclusions:

• Lithium and triiodothyronine (T3) augmentation of tricyclic agents are well-studied strategies.
• Evidence indicates the effectiveness of some atypical antipsychotics in augmenting selective serotonin reuptake inhibitors for TRD.
• There is a need for more robust, adequately powered controlled trials on augmentation pharmacotherapy for TRD.